GCG and diabetes mellitus: In the context of incretin-based diabetes disease therapy, the enhancement of endogenous GLP-1 secretion represents a novel alternative treatment that more closely resembles the physiology of the peptide.18 19 Here, we demonstrated the therapeutic effect of secreted endogenous peptides with encapsulated synthetic analogues within a lipid-based drug delivery system as an innovative approach for the oral delivery of peptides.